ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,149.27
0.79%
Dow Jones
43,958.51
1.27%
Gold vs US Dollar
2,669.755
0.65%
Brent Oil
73.60
1.04%
Bitcoin
98,110.40
3.98%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Astria Therapeutics Inc (ATXS)

  7. Astria Therapeutics Inc (ATXS) News

Astria Therapeutics (ATXS)

Astria Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ATXS
DateTimeSourceHeadlineSymbolCompany
14/11/202422:45Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ATXSAstria Therapeutics Inc
14/11/202421:15Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ATXSAstria Therapeutics Inc
14/11/202417:03Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ATXSAstria Therapeutics Inc
13/11/202421:21Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ATXSAstria Therapeutics Inc
13/11/202421:10Business WireAstria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate UpdateNASDAQ:ATXSAstria Therapeutics Inc
13/11/202421:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ATXSAstria Therapeutics Inc
13/11/202413:00Business WireAstria Therapeutics to Present at Upcoming Jefferies London Healthcare ConferenceNASDAQ:ATXSAstria Therapeutics Inc
08/11/202419:17Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ATXSAstria Therapeutics Inc
04/11/202421:10Business WireAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ATXSAstria Therapeutics Inc
30/10/202412:00Business WireAstria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific MeetingNASDAQ:ATXSAstria Therapeutics Inc
21/10/202412:00Business WireAstria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific MeetingNASDAQ:ATXSAstria Therapeutics Inc
16/10/202412:00Business WireEuropean Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics’ Investigational Therapy for the Treatment of Hereditary AngioedemaNASDAQ:ATXSAstria Therapeutics Inc
02/10/202420:10Business WireAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ATXSAstria Therapeutics Inc
30/09/202412:00Business WireAstria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary AngioedemaNASDAQ:ATXSAstria Therapeutics Inc
27/09/202412:00Business WireAstria Therapeutics to Present at Upcoming Global Angioedema ForumNASDAQ:ATXSAstria Therapeutics Inc
19/09/202412:00Business WireAstria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology CongressNASDAQ:ATXSAstria Therapeutics Inc
04/09/202420:10Business WireAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ATXSAstria Therapeutics Inc
30/08/202412:00Business WireAstria Therapeutics to Present at Upcoming Bradykinin SymposiumNASDAQ:ATXSAstria Therapeutics Inc
29/08/202412:00Business WireAstria Therapeutics to Participate in Upcoming Morgan Stanley 22nd Annual Global Healthcare ConferenceNASDAQ:ATXSAstria Therapeutics Inc
12/08/202420:56Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ATXSAstria Therapeutics Inc
12/08/202420:10Business WireAstria Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate UpdateNASDAQ:ATXSAstria Therapeutics Inc
12/08/202420:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ATXSAstria Therapeutics Inc
12/08/202420:00Business WireAstria Therapeutics Chooses Ypsomed’s YpsoMate as the Injection Device for STAR-0215 for the Treatment of Hereditary AngioedemaNASDAQ:ATXSAstria Therapeutics Inc
07/08/202412:00Business WireAstria Therapeutics to Participate in Upcoming 2024 Wedbush PacGrow Healthcare ConferenceNASDAQ:ATXSAstria Therapeutics Inc
02/08/202420:10Business WireAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ATXSAstria Therapeutics Inc
02/07/202420:10Business WireAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ATXSAstria Therapeutics Inc
06/06/202420:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATXSAstria Therapeutics Inc
06/06/202420:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATXSAstria Therapeutics Inc
06/06/202420:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATXSAstria Therapeutics Inc
06/06/202420:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATXSAstria Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ATXS

Your Recent History

NYSE
NSCO
Nesco
DOWI
DJUSSF
DJ US Consumer Finance
FTSE
E3020
FTSEurofirst 300 Financi...
BIT
1VAR
Varta
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved

    BLACK FRIDAY

    ADVFN

    Celebrating 25 years Est 1999-2024

    Save up to 60%* for Level 2 Lite

    1 year 40%, 2 years 50% and *3 years 60%
    EU Flag

    *Across 3 years £2132.64 only £853.06